

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Deshpande et al.

Serial No.: 09/791,153

Group Art Unit No.: 1644

Filed: February 22, 2001

Examiner: Schwadron, Ronald B.

For: Selective Binding Agents of
Osteoprotegerin Binding Protein

Confirmation No.: 7448

Docket No.: A-633A

**RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT
AND PRELIMINARY AMENDMENT**Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

A response to the Notice of Non-Compliant Amendment dated July 22, 2009 and
a Preliminary Amendment are filed herewith.

Amendments to the Claims are reflected in the listing of claims which begins on page
2 of this paper.

Remarks/Arguments begin on page 4 of this paper.

CERTIFICATE OF EFS-WEB TRANSMISSION

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted electronically through
EFS-WEB to the Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on the date appearing below.

Date: August 21, 2009/Nola J. Diamond/

Nola J. Diamond

AMENDMENT

Please amend the claims as follows.

Listing of Claims

1-39. (cancelled)

40. (currently amended) An antibody or antigen binding domain which recognizes a DE epitope on human osteoprotegerin binding protein (OPGbp) wherein the DE epitope comprises the amino acid sequence from residues 212 to 250 of human OPGbp as shown in Figure 29 (SEQ ID NO: 158).

41. (currently amended) ~~An~~ The antibody or antigen binding domain of Claim 40 which recognizes a wherein the DE epitope comprises residues 230 to 234 of ~~an~~ human OPGbp as shown in Figure 29 (SEQ ID NO: 158).

42. (currently amended) The antibody or antigen binding domain of Claim 40 or 41 ~~wherein the DE epitope comprises~~ which recognizes the sequence Asp-Leu-Ala-Thr-Glu of human OPGbp.

43. (original) An antibody or antigen binding domain which binds to murine OPGbp comprising the amino acid substitutions S229D, V230L, P231A, and D233E, but does not bind to murine OPGbp lacking said substitutions.

44. (currently amended) The antibody or antigen binding domain of Claims 40, 41, 42 or 43 which inhibits the formation ~~ef~~ or activation of osteoclasts.

45. (original) The antibody or antigen binding domain of Claims 40, 41, 42 or 43 which inhibits bone resorption.

46-51. (cancelled)

52. (currently amended) An The antibody or antigen binding domain of Claims 40, 41, 42 or 43 which binds selectively to human OPGbp with a dissociation constant (KD) of about 1nM or less.

53. (currently amended) An The antibody or antigen binding domain of Claims 40, 41, 42 or 43 which binds selectively to human OPGbp with a dissociation rate constant (kd) of about 3×10^{-3} or less.

54. (new) The antibody or antigen binding domain of Claims 40, 41, 42 or 43 wherein the antibody is a monoclonal antibody.

55. (new) The antibody or antigen binding domain of Claims 40, 41, 42 or 43 wherein the antibody is a chimeric, humanized, human, single chain or bispecific antibody.

56. (new) The antibody or antigen binding domain of Claims 40, 41, 42 or 43 wherein the antigen binding domain is a Fab, F(ab)', F(ab)'', Fv or sFv fragment.

57. (new) The antibody or antigen binding domain of Claims 40, 41, 42 or 43 which comprises an IgG isotype.

58. (new) A composition comprising the antibody or antigen binding domain of Claims 40, 41, 42 or 43 and a pharmaceutically acceptable agent.

Remarks/Arguments

The Claims

Claims 10-20, 27-29 and 40-53 are currently pending in the application with Claims 48-51 being withdrawn from further consideration as being drawn to a non-elected species.

Notice of Non-Complaint Amendment

In the communication of July 20, 2009, the Examiner noted that the amendments filed on December 19, 2007 and March 24, 2004 were considered non-compliant because Claims 48-51 drawn to non-elected species and withdrawn from further consideration were not indicated as "withdrawn" in the listing of claims.

Claims 48-51 have been cancelled in the Preliminary Amendment filed herewith, thereby bringing the amendment into compliance.

Preliminary Amendment

Applicants hereby cancel Claims 10-20, 27-29 and 46-51 without prejudice or disclaimer and add new Claims 54-58. Upon cancellation of these claims, Claims 40-45 and 52-58 will be pending in the application.

Claim 40 has been amended to recite an antibody or antigen binding domain which recognizes a DE epitope on human OPGbp "wherein the DE epitope comprises the amino acid sequence from residues 212 to 250 of human OPGbp as shown in Figure 29 (SEQ ID NO: 158)". Support for this amendment is found at p. 38, line 33 to p. 39, line 5 of the specification.

Claim 41 has been amended to recite a DE epitope that "comprises residues 230 to 234 of human OPGbp". Support for this amendment is found at p. 39, lines 12-18 of the specification.

New Claims 54-58 are supported at various locations in the specification, including p. 32, lines 8-12; p. 33, lines 5-12; and p. 72, lines 8-12 of the specification.


The new and amended claims do not add new matter or raise new issues requiring further searching and consideration. Applicants respectfully request entry of the new and amended claims.

CONCLUSION

Claims 40-45 and 52-58 are in condition for allowance and a notice thereof is solicited.

Although Applicants believe that no fee is due herewith, the Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,



Robert B. Winter
Attorney/Agent for Applicant(s)
Registration No.: 34,458
Phone: (805) 447-2425
Date: August 21, 2009

Please send all future correspondence to:
21069
US Patent Operations/RBW
Dept. 4300, M/S 28-2-C
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

Electronic Acknowledgement Receipt

EFS ID:	5935579
Application Number:	09791153
International Application Number:	
Confirmation Number:	7448
Title of Invention:	Selective binding agents of osteoprotegerin binding protein
First Named Inventor/Applicant Name:	Rajendra V. Deshpande
Correspondence Address:	U.S. Patent Operations/RBW Dept. 4300, M/S 27-4-A AMGEN, INC. One Amgen Center Drive Thousand Oaks CA 91320-1799 US - -
Filer:	Robert B. Winter/Nola Diamond
Filer Authorized By:	Robert B. Winter
Attorney Docket Number:	A-633A
Receipt Date:	21-AUG-2009
Filing Date:	22-FEB-2001
Time Stamp:	22:12:26
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
File Listing:	

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	SimonetCell1997.pdf	1137987	no	11
			005430e95c5d4f90b1a7b7fe311344b73ee3266a		
Warnings:					
Information:					
2	NPL Documents	SkolnickTrendsInBiotech2000.pdf	6195199	no	6
			13183c0763423e0c3893d89460446c0995a0b14273		
Warnings:					
Information:					
3	NPL Documents	SmithCell1994.pdf	483706	no	5
			7c3fc0d5a060977c2edc1edbf8a1c7543708		
Warnings:					
Information:					
4	NPL Documents	StamenkovicEMBO_J1989.pdf	816885	no	8
			5f53d399c034a30899b790dab5cc5a8531f1b877		
Warnings:					
Information:					
5	NPL Documents	StressgenProdUseSheet-RANKL_TRANCEMonoclonalAB-Clone12A668.pdf	73049	no	1
			4093988f96cf58cd423b77ab5fa028e7c2cd8b3		
Warnings:					
Information:					
6	NPL Documents	SudaBone1995.pdf	491833	no	5
			971d86cebb3d9d11f45c0ee495ce35596a282fb		
Warnings:					
Information:					
7	NPL Documents	SudaEndocRevMonograph1995.pdf	467505	no	5
			304fcb70553ba6ca11d77cf1182221b890a908d		
Warnings:					
Information:					
8	NPL Documents	SudaEndocrineRev1999.pdf	1273553	no	14
			de46004c12c2aa088e0830853f3d16818048453		
Warnings:					
Information:					
9	NPL Documents	TakadaBoneMineral1992.pdf	1782601	no	15
			92d9f5be93c0fc0b0de75869364e461c19f6226		

Warnings:					
Information:					
10	NPL Documents	TakeyamaBiochemBiophysRes Comm2000.pdf	438718 e9bcbf8edc088e00069d9f5440054092d8b c0bae	no	6
Warnings:					
Information:					
11	NPL Documents	TengJClInInvest2000.pdf	1278975 4f0492ce9d487e353d4e61eb78e167c7d46 2ef	no	18
Warnings:					
Information:					
12	NPL Documents	TsudaBiochemBiophysResCom m1997.pdf	549605 cc82556da6b55bbedda3178b08b5c10b1 22e60b	no	7
Warnings:					
Information:					
13	NPL Documents	UdagawaBone1999.pdf	682032 0185e1b3180a7818e4d9d2c22f1554a66b36 9d13	no	8
Warnings:					
Information:					
14	NPL Documents	VineyJImmunol1998.pdf	367004 8a045588005a26eef2483a3b7c236e46298 8e42	no	11
Warnings:					
Information:					
15	NPL Documents	WatanabeBiochemBiophysRes Comm1990.pdf	876623 8ae0073ccedf808a3cc9f80930a68a359d30 2478	no	8
Warnings:					
Information:					
16	NPL Documents	WillardProteinExpressionPurific ation2000.pdf	922887 c1d43433c0ff0488aee25d0e96a05d181ac53 da1	no	11
Warnings:					
Information:					
17	NPL Documents	WongJBiolChem1997.pdf	421575 d8d7cc4f5e5d1591597340f91e03879c3a0 484	no	5
Warnings:					
Information:					
18	NPL Documents	ShalhoubJCellBiochem1999. pdf	3615910 a04b6e5ccc0a0d0fd49ad206a9b166dfc 3ff	no	11

Warnings:					
Information:					
19	NPL Documents	SudaEndocRev1992.pdf	1161023 d6c621c4d8b8b0cc2c6877917281b9a0e28255	no	1
Warnings:					
Information:					
20	NPL Documents	WileyImmunity1995.pdf	8407990 42c6927b6c95986332180b61829ae02a85c81910b	no	10
Warnings:					
Information:					
21	NPL Documents	WongJExpMed1997.pdf	5188582 79a0bb1c911681580ee761ee8bb202740f649eb	no	6
Warnings:					
Information:					
22	NPL Documents	WongJBiolChem1998.pdf	402415 1c5ace7a84cd99c739c952817e217d09a07a826f	no	5
Warnings:					
Information:					
23	NPL Documents	XulImmunity1996.pdf	686913 63ae5834da56cb1d3e1c5c16c3d86c8857c0884	no	9
Warnings:					
Information:					
24	NPL Documents	YangProcNatlAcadSciUSA1985.pdf	4566471 63228c08ff0ba0dced13c76cb1a0ec12b08670c	no	5
Warnings:					
Information:					
25	NPL Documents	YasudaPNAS1998.pdf	336481 8a64b2f1341c53b2d1133f62d93cd7725c5c03618	no	6
Warnings:					
Information:					
26	NPL Documents	YonedaCancerRes1995.pdf	550720 8af3ac15c6d66a0a6d306a020d4f5af190818	no	6
Warnings:					
Information:					
27	NPL Documents	YunImmunol1998.pdf	1303007 d40132587d5c08b0a942ee6c8bdab6c2062a	no	9

Warnings:					
Information:					
28	NPL Documents	ZhangJBIolChem2001.pdf	568959 6222e3fc04807480e9a208db7d6034703f1a8d	no	6
Warnings:					
Information:					
29	NPL Documents	HymowitzBiochemistry2000.pdf	545746 9386392c0f6a71a05ee4253472b48100c17726	no	8
Warnings:					
Information:					
30	NPL Documents	MongkolsapayaNatureStructBiol1999.pdf	6938798 2991525a8fe1efb1aaefce0678a9646c1eb606d	no	6
Warnings:					
Information:					
31	NPL Documents	ParslowMedImmunology1997.pdf	1810718 d11ae64008fc0538a0944b1b7a805c00c8f49984	no	11
Warnings:					
Information:					
32	NPL Documents	ChalmImmunity1999.pdf	8632804 3c1c23b1549c6b208dc5fa3c6eae08b65c05a09f	no	9
Warnings:					
Information:					
33	Information Disclosure Statement (IDS) Filed (58/08)	A-633ASupp1449-5of5-082109.pdf	600762 d694a1cd2de1400b6a3c9f18e04c0c57753d4d92	no	2
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
34	Power of Attorney	A-633APowerOfAtty082109.pdf	51685 0d72ed444d4dc7b14111e317652d3909c977061	no	1
Warnings:					
Information:					
35		A-633A-ResponseToNotice082109.pdf	155654 18c0c611f8bca375423a94486444cd8bca7730	yes	5
Multipart Description/PDF files in .zip description					
Document Description			Start	End	

	Preliminary Amendment	1	1
	Claims	2	3
	Applicant Arguments/Remarks Made in an Amendment	4	5

Warnings:

Information:

Total Files Size (in bytes):

63784375

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.